🔹 Revenue: $2.41B (Est. $2.24B) 🟢; UP +25% YoY
🔹 EPS: $2.21 (Est. $1.75) 🟢; UP +38% YoY
🔹 Net Income (Non-GAAP): $805M (UP +40% YoY)
Segment Revenue:
Instruments and Accessories:
🔹 Revenue: $1.41B (Est. $1.35B) 🟢; UP +23% YoY
🔸 Growth driven by an 18% increase in da Vinci procedure volume and 70% growth in Ion procedure volume.
Systems Revenue:
🔹 Revenue: $655M (Est. $536.22M) 🟢; UP +36% YoY
🔸 Includes 493 da Vinci surgical systems placed, up from 415 YoY.
Services Revenue:
🔹 Revenue: $346M (Est. $346.12M) 🟡
Operational Highlights:
🔹 Worldwide da Vinci Procedures: Grew +18% YoY in Q4 2024.
🔹 da Vinci Surgical System Placements: 493 systems, including 174 da Vinci 5 systems; Installed base increased to 9,902 (UP +15% YoY).
🔹 Operating Income (Non-GAAP): $928M (UP +49% YoY).
🔹 Operating Income (GAAP): $735M (UP +63% YoY).
2025 Guidance:
🔹 Worldwide da Vinci Procedure Growth: 13%-16% (2024 growth: 17%).
🔹 Non-GAAP Gross Margin: 67%-68% (2024: 69.1%).
🔹 Operating Expense Growth: 10%-15% (2024: 10%).
Cash Flow & Financial Health:
🔹 Cash, Cash Equivalents, and Investments: $8.83B (UP $521M QoQ).
🔹 Free Cash Flow: $878M (Est. $878M) 🟡.
CEO Commentary:
🔸 "Strong procedure growth, driven by continued adoption of the da Vinci system and increased Ion procedure volumes. We’ve expanded our installed base significantly, ensuring broader access to minimally invasive care."
Additional Insights:
🔹 Foundation Contributions: $45M in Q4 2024 (up from $40M YoY).
🔹 Leasing Trends: Increase in systems placed under usage-based leases (140 systems in Q4 2024 vs. 109 YoY).
🔹 R&D Investment: Focus on developing advanced robotics and broadening the system’s accessibility.